[go: up one dir, main page]

WO2014042433A3 - Compounds and compositions for modulating adenosine a3 receptor activity - Google Patents

Compounds and compositions for modulating adenosine a3 receptor activity Download PDF

Info

Publication number
WO2014042433A3
WO2014042433A3 PCT/KR2013/008229 KR2013008229W WO2014042433A3 WO 2014042433 A3 WO2014042433 A3 WO 2014042433A3 KR 2013008229 W KR2013008229 W KR 2013008229W WO 2014042433 A3 WO2014042433 A3 WO 2014042433A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compositions
receptor activity
modulating adenosine
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/008229
Other languages
French (fr)
Other versions
WO2014042433A2 (en
Inventor
MinJeong CHOI
Su-Sung OH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kainos Medicine Inc
Original Assignee
Kainos Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kainos Medicine Inc filed Critical Kainos Medicine Inc
Publication of WO2014042433A2 publication Critical patent/WO2014042433A2/en
Publication of WO2014042433A3 publication Critical patent/WO2014042433A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides for Adenosine A3 receptor agonists, and also methods and use of the compounds of the invention, by themselves or in combination with other therapies, for treating a disease, disorder, or condition.
PCT/KR2013/008229 2012-09-14 2013-09-11 Compounds and compositions for modulating adenosine a3 receptor activity Ceased WO2014042433A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700924P 2012-09-14 2012-09-14
US61/700,924 2012-09-14

Publications (2)

Publication Number Publication Date
WO2014042433A2 WO2014042433A2 (en) 2014-03-20
WO2014042433A3 true WO2014042433A3 (en) 2014-05-08

Family

ID=50278812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/008229 Ceased WO2014042433A2 (en) 2012-09-14 2013-09-11 Compounds and compositions for modulating adenosine a3 receptor activity

Country Status (1)

Country Link
WO (1) WO2014042433A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130862T1 (en) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
UA111163C2 (en) 2010-07-22 2016-04-11 Гайлід Сайєнсіз, Інк. METHODS AND COMPOUNDS FOR THE TREATMENT OF Viral Infections of PARAMYXOVIRIDAE
JP2014517079A (en) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
PT4190786T (en) 2012-12-07 2025-05-29 Vertex Pharma Compounds useful as inhibitors of atr kinase
JP2016512239A (en) 2013-03-15 2016-04-25 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinase
JP2016512816A (en) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinase
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
KR102575125B1 (en) 2014-06-05 2023-09-07 버텍스 파마슈티칼스 인코포레이티드 Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
RU2736219C2 (en) 2014-06-17 2020-11-12 Вертекс Фармасьютикалз Инкорпорейтед Method of treating cancer using a combination of chk1 and atr inhibitors
TWI767201B (en) * 2014-10-29 2022-06-11 美商基利科學股份有限公司 Methods for treating filoviridae virus infections
MA52371A (en) 2015-09-16 2021-09-22 Gilead Sciences Inc METHODS OF TREATING CORONAVIRIDAE INFECTIONS
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017172596A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CA3056072C (en) 2017-03-14 2022-08-23 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
JP2020518578A (en) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド (S)-2-Ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine-7 -Yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate crystalline form
ES3000461T3 (en) 2017-07-11 2025-02-28 Gilead Sciences Inc Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CN109748921B (en) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-tert-butoxycarbonyl-protected heterocyclic compounds, methods for their preparation and methods for preparing C-nucleoside analogs
JP2023512656A (en) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド Methods for treating SARS CoV-2 infection
CN112321589B (en) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 Synthesis method of antiviral drug Reidesciclovir and intermediate thereof
CN111233869B (en) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 New compounds for preparing key intermediates of Remdesivir and preparation method thereof
TWI890963B (en) 2020-03-12 2025-07-21 美商基利科學股份有限公司 Methods of preparing 1'-cyano nucleosides
AU2021251689B2 (en) 2020-04-06 2024-06-13 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202532084A (en) 2020-05-29 2025-08-16 美商基利科學股份有限公司 Remdesivir treatment methods
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
CN111793101B (en) 2020-07-17 2022-09-30 四川大学 Process for the synthesis of C-nucleoside compounds
PE20231983A1 (en) 2020-08-27 2023-12-12 Gilead Sciences Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
CA3244278A1 (en) 2022-03-02 2023-09-07 Gilead Sciences Inc Compounds and methods for treatment of viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132135A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2009132123A1 (en) * 2008-04-23 2009-10-29 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2011035250A1 (en) * 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
WO2012012776A1 (en) * 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMMY E. METOBO ET AL.: "'Practical synthesis of l' -substituted Tubercidin C-nucleoside analogs'", TETRAHEDRON LETTERS, vol. 53, 2012, pages 484 - 486 *

Also Published As

Publication number Publication date
WO2014042433A2 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
WO2014042433A3 (en) Compounds and compositions for modulating adenosine a3 receptor activity
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
TN2017000129A1 (en) Antibody molecules to pd-l1 and uses thereof
HK1202377A1 (en) Modulating certain tyrosine kinases
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
HK1225718A1 (en) Biaryl acetamide compounds and methods of use thereof
WO2013138568A8 (en) Liver x receptor modulators
MX354818B (en) Liver x receptor modulators.
HRP20180659T1 (en) AMORPHIC SOLID DISPERSION INTENDED FOR USE IN THE TREATMENT OF BRAIN CANCER
NZ713080A (en) Pyridin-4-yl derivatives
HK1243430A1 (en) Methods for treating dry eye disease by administering an il-6r antagonist
WO2012138223A3 (en) Compounds and methods for altering activin receptor-like kinase signalling
PT2748147T (en) Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
WO2012061536A3 (en) Methods for treating hair loss disorders
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
WO2014047551A8 (en) Flavonoid based antiviral targets
MX2015012043A (en) Muscarinic agonists.
SG11201403887WA (en) Methods for preventing, treating or diagnosing disorders
TN2014000391A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
TN2016000233A1 (en) Adenosine a1 agonists as medicaments against renal diseases.
EP2952204A4 (en) Pharmaceutical composition for reducing or inhibiting scar formation, containing bmp-7 and diluting agent
Abrams Jews with Pharaoh’s Values: Why Southern Jews Fought and Died for the Confederacy
TN2014000207A1 (en) Anti il-36r antibodies
MX2013013071A (en) Molecule for treating an inflammatory disorder.

Legal Events

Date Code Title Description
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 03.07.2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13836662

Country of ref document: EP

Kind code of ref document: A2